Literature DB >> 1731521

Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue.

P L Porter1, A M Gown, S G Kramp, M D Coltrera.   

Abstract

p53 is a nuclear protein believed to play an important role, through mutation and overexpression, in the progression of human malignant tumors. The authors employed a monoclonal antibody, 1801, and investigated overexpression of p53 in a series of 255 malignant and benign tumors, using deparaffinized sections of methacarn-fixed tissue. Overall, immunohistochemically detected p53 overexpression was found in 39% of malignant tumors, with considerable variation within individual tumor types (34% of breast carcinomas, 92% of ovarian carcinomas, 33% of soft tissue sarcomas). Homogenous, heterogenous, and focal immunostaining patterns were noted. With rare exceptions, no immunostaining of any benign tumors was noted. No immunostaining was found in adjacent, benign tissues, or in a series of fetal tissues. This is the first demonstration of widespread p53 overexpression in alcohol-fixed, embedded tissue and confirms the major role played by p53 in human malignancies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1731521      PMCID: PMC1886248     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  37 in total

1.  Genetic mechanisms of tumor suppression by the human p53 gene.

Authors:  P L Chen; Y M Chen; R Bookstein; W H Lee
Journal:  Science       Date:  1990-12-14       Impact factor: 47.728

2.  Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation.

Authors:  P Hinds; C Finlay; A J Levine
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

3.  Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression.

Authors:  L Banks; G Matlashewski; L Crawford
Journal:  Eur J Biochem       Date:  1986-09-15

4.  Mutant p53 proteins bind hsp 72/73 cellular heat shock-related proteins in SV40-transformed monkey cells.

Authors:  H W Stürzbecher; P Chumakov; W J Welch; J R Jenkins
Journal:  Oncogene       Date:  1987-05       Impact factor: 9.867

5.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.

Authors:  C A Finlay; P W Hinds; T H Tan; D Eliyahu; M Oren; A J Levine
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

6.  High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene.

Authors:  A Lavigueur; V Maltby; D Mock; J Rossant; T Pawson; A Bernstein
Journal:  Mol Cell Biol       Date:  1989-09       Impact factor: 4.272

7.  Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder.

Authors:  A F Olumi; Y C Tsai; P W Nichols; D G Skinner; D R Cain; L I Bender; P A Jones
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

Review 8.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

9.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

10.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

View more
  50 in total

1.  Detection and monitoring of serum p53 antibodies in patients with colorectal cancer.

Authors:  P Hammel; B Boissier; M T Chaumette; P Piedbois; N Rotman; J C Kouyoumdjian; R Lubin; J C Delchier; T Soussi
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

2.  p53 expression in lymphatic malignancies.

Authors:  Y Soini; P Pääkkö; M Alavaikko; K Vähäkangas
Journal:  J Clin Pathol       Date:  1992-11       Impact factor: 3.411

3.  Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas.

Authors:  B S Chozick; D L Benzil; E G Stopa; J C Pezzullo; N W Knuckey; M H Epstein; S D Finkelstein; P W Finch
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

4.  p53 gene product expression in resected non-small cell carcinoma of the lung, with studies of concurrent cytological preparations and microwave antigen retrieval.

Authors:  S Binks; C A Clelland; J Ronan; J Bell
Journal:  J Clin Pathol       Date:  1997-04       Impact factor: 3.411

5.  p53 immunoreactivity in cervical intraepithelial neoplasia and non-neoplastic cervical squamous epithelium.

Authors:  M D Jeffers; J Richmond; M Farquharson; A M McNicol
Journal:  J Clin Pathol       Date:  1994-12       Impact factor: 3.411

6.  Search for accumulation of p53 protein and detection of human papillomavirus genomes in sebaceous gland carcinoma of the eyelid.

Authors:  N Hayashi; M Furihata; Y Ohtsuki; H Ueno
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

7.  Comparative analysis of p53 and c-myc expression and cell proliferation in human hepatocellular carcinomas--an enhanced immunohistochemical approach.

Authors:  M Saegusa; Y Takano; H Kishimoto; G Wakabayashi; K Nohga; M Okudaira
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

8.  High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma.

Authors:  E Cesarman; G Inghirami; A Chadburn; D M Knowles
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

9.  Synchronous colon carcinomas: molecular-genetic evidence for multicentricity.

Authors:  R J Koness; T C King; S Schechter; S F McLean; C Lodowsky; H J Wanebo
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

10.  Malignant mixed Mullerian tumors of the uterus: histopathological evaluation of cell cycle and apoptotic regulatory proteins.

Authors:  Rani Kanthan; Jenna-Lynn B Senger; Dana Diudea
Journal:  World J Surg Oncol       Date:  2010-07-19       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.